AUTHORS
Michael Wang, MD, Joanna Romejko-Jarosinska, MD, PhD2, Wojciech Jurczak, MD, PhD3, Sunil Iyengar, PhD4, Abel Costa, MD5, Nimish Shah, MD, MRCP, FRCPath6, Monique Menzies Wojtowicz, BAppSc(Pthy), MBBS(Hons), MClinTRes7, Allison Winter, MD8, Adam Witkowski, MD9, Neil Chua, MD10, Ana Jiménez Ubieto, MD, PhD11, John Kuruvilla, MD12, Diego Villa, MD13, Chan Cheah, MBBS, DMSc14, Andre Goy, MD15, Elise A. Chong, MD16, Andrew Wood, FRCPath, PhD17, Rachel Fletcher, PhD18, Stefanie Meyer19, Rebecca Silva, PhD20, Simon Rule21, Eliza A Hawkes, MD22
AFFILIATIONS
1 Department of Lymphoma/Myeloma, MD Anderson Cancer Center, University of Texas, Houston, United States
2 Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
3 Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
4 Department of Haematology, Royal Marsden Hospital, London, United Kingdom
5 Department of Hematology, D’or Institute for Research and Education, São Paulo, Brazil
6 Department of Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
7 Macquarie University Hospital, Macquarie University, Sydney, Australia
8 Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
9 Hematology Department, Pomeranian Hospitals, Gdynia, Poland
10 Department of Medical Oncology, Cross Cancer Institute, Edmonton, Canada
11 Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
12 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
13 Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada
14 Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia and Medical School, University of Western Australia, Perth, Australia
15 John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, United States
16 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, United States
17 AstraZeneca, Cambridge, United Kingdom
18 AstraZeneca, Cambridge, United Kingdom
19 AstraZeneca, Waltham, United States
20 AstraZeneca, Gaithersburg, United States
21 AstraZeneca, Cambridge, United Kingdom
22 Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia
ABSTRACT
Introduction: Mantle cell lymphoma (MCL) is a rare and generally incurable B-cell non-Hodgkin lymphoma for which frontline treatment has traditionally relied on chemoimmunotherapy (CIT). While Bruton tyrosine kinase inhibitors (BTKis) are approved in combination with CIT for treatment-naive (TN) MCL, there is growing interest in novel, chemotherapy-free BTKi-based combinations aimed at improving outcomes while reducing treatment burden.
The ongoing phase 2 TrAVeRse study (NCT05951959) evaluates a fixed-duration, chemotherapy-free combination of acalabrutinib, venetoclax, and rituximab (AVR) in TN MCL; initial efficacy and safety findings have been reported, which demonstrated an end-of-induction minimal residual disease-negative complete response (MRD-neg CR) rate of 82% (Hawkes et al. ASH 2025). After induction, TrAVeRse also evaluates finite vs continuous BTKi therapy by randomizing patients (pts) with end-of-induction MRD-neg CR to acalabrutinib monotherapy or observation. We now report updated progression-free survival (PFS) and overall survival (OS) data.
Methods: Pts were aged ≥18 y with TN MCL requiring treatment, radiologically measurable disease, and ECOG PS 0‒2. Pts received AVR induction in 28-day cycles (C) consisting of acalabrutinib 100 mg BID C1‒C13, venetoclax (C2‒C13), and rituximab (375 mg/m2 on day [D] 1 of C1‒12). During C14, acalabrutinib was administered while awaiting MRD results. Pts who achieved MRD-neg CR at end of C13 were randomized 1:1 on C15D1 to either continued acalabrutinib monotherapy until progressive disease (PD) or unacceptable toxicity, or observation until PD, with the option to restart acalabrutinib at clinical relapse.
Results: Between January and July 2024, 108 pts were treated across 7 countries. Median age was 69 y, with 74% male and 87% White. Most pts had stage IV disease (92%), extranodal involvement (94%), and bone marrow involvement (83%). p53 expression by IHC was positive in 31% of pts, TP53 was mutated (TP53m) in 19% of pts (17/90 with available TP53 results), 31% had high-risk simplified MIPI score, 8% had blastoid/pleomorphic histology, and 38% had Ki-67 ≥30%.
At the updated data cutoff of June 19, 2026 (29 mo after first pt treated), median follow-up was 23.3 mo. Of the 108 treated pts, 106 received AVR (2 did not initiate venetoclax), 95 (88%) completed AVR induction, and 89 (82%) were randomized to observation or continued acalabrutinib monotherapy. Among the 106 pts who received AVR, 11 (10%) discontinued all treatments due to adverse events (n=6), PD (n=4), or other reasons (n=1). At data cutoff, 99/108 (92%) pts remained on study; discontinuations were due to death (n=7) or withdrawal of consent (n=2).
Median PFS was not reached. The estimated 22-mo PFS and OS rates from treatment initiation among all 108 pts were 89% and 94%, respectively. Among the 89 randomized pts, most remained in CR at data cutoff; only 2 had progressed (1 TP53m positive), and 1 died without prior PD due to myocardial infarction. Among the 89 pts randomized, the estimated 22-mo PFS and OS rates were 96% and 99%, respectively.
Clinical benefit was also maintained in pts with TP53m. Of 17 pts with confirmed TP53m, 14 (82%) achieved end-of-induction MRD-neg CR, and all 14 were randomized. In the overall TP53m subgroup, median PFS was not reached; 3 pts had PD, and the estimated 22-mo PFS and OS rates were 82% and 94%, respectively. Among the 14 randomized pts, only 1 PD had occurred at data cutoff, and the estimated 22-mo PFS and OS rates were 92% and 100%, respectively.
Updated efficacy and safety data, including the first post-randomization assessment of continued acalabrutinib monotherapy vs observation, together with updated MRD and survival outcomes in the overall and TP53m cohorts, will be presented with an expected median follow-up of 26 mo.
Conclusion: With nearly 2 yr follow-up, AVR continues to be a highly effective fixed-duration, chemotherapy-free frontline regimen in an all-comers MCL population, with durable responses and encouraging survival, including in pts with TP53m. With longer follow-up and the first post-randomization analysis forthcoming, TrAVeRse will inform whether treatment discontinuation after MRD-neg CR can maintain disease control while reducing treatment exposure.
DISCLOSURES
Michael Wang, MD: SOHO Asia - Honoraria; CAHON - Honoraria; UPMC Hillman Cancer Center - Honoraria; Scientific Education Support, MJH Life Sciences - Honoraria; Genentech - Honoraria; Lymphoma Research Foundation - Honoraria; Veteran Affairs Office - Honoraria; MD Education - Honoraria; Genentech - Honoraria; Ottawa Hospital - Honoraria; Scholars in Medicine - Honoraria; AstraZeneca - Honoraria; BeOne Medicines, Ltd - Honoraria; Scientific Education Support - Honoraria; Kite Pharma - Honoraria; Scripps - Honoraria; Hospital Sirio Libanes - Honoraria; Eli Lilly - Research Funding; Nurix Therapeutics - Research Funding; InnoCare - Research Funding; Bantam Pharma - Research Funding; Loxo Oncology - Research Funding; Kite Pharma - Research Funding; Velosbio - Research Funding; AbbVie - Research Funding; Incyte - Research Funding; Juno Therapeutics - Research Funding; Genentech - Research Funding; Pharmacyclics - Research Funding; Genmab - Research Funding; Inctye - Research Funding; Oncternal Therapeutics - Research Funding; AstraZeneca - Research Funding; Janssen - Research Funding; BeOne Medicines, Ltd - Research Funding; OncLive - Patents & Royalties; BMS - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); InnoCare - Consultancy (Includes expert testimony); Galapagos NV - Consultancy (Includes expert testimony); Pepromene Bio - Consultancy (Includes expert testimony)